Affiliation:
1. College of Pharmacy, Chung-Ang University
Publisher
Pharmaceutical Society of Japan
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference43 articles.
1. 1) Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child., 140, 543–546 (1986).
2. 2) Choi EH, Lee HJ, Chanock SJ. Human genetics and respiratory syncytial virus disease: Current findings and future approaches. Challenges and opportunities for respiratory syncytial virus vaccines. (Anderson LJ, Graham BS eds.) Springer, New York, p. 123 (2013).
3. 3) Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the paediatric population in Spain. Epidemiol. Infect., 131, 867–872 (2003).
4. 4) Meissner HC. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr. Infect. Dis. J., 22 (Suppl.), S40–S45, discussion, S44–S45 (2003).
5. 5) Vandini S, Bottau P, Faldella G, Lanari M. Immunological, viral, environmental, and individual factors modulating lung immune response to respiratory syncytial virus. Biomed Res. Int., 2015, 875723 (2015).